Multivariable Cox regression analysis of the association between early POD and risk of death
| Variable . | Adverse factor* . | Adjusted HR (95% CI) . | P . |
|---|---|---|---|
| Progression as a time varying covariate | Early POD (<2 y) | 3.6 (2.6-5.1) | <.01 |
| Age | Age ≥75 y | 2.2 (1.6-3.0) | <.01 |
| Comorbidity | Charlson comorbidity index ≥3 | 2.1 (1.5-2.8) | <.01 |
| Treatment duration | Treatment duration ≤4 mo | 1.8 (1.3-2.5) | <.01 |
| Disease stage | Rai stage ≥II | 1.4 (1.1-2.0) | .01 |
| Variable . | Adverse factor* . | Adjusted HR (95% CI) . | P . |
|---|---|---|---|
| Progression as a time varying covariate | Early POD (<2 y) | 3.6 (2.6-5.1) | <.01 |
| Age | Age ≥75 y | 2.2 (1.6-3.0) | <.01 |
| Comorbidity | Charlson comorbidity index ≥3 | 2.1 (1.5-2.8) | <.01 |
| Treatment duration | Treatment duration ≤4 mo | 1.8 (1.3-2.5) | <.01 |
| Disease stage | Rai stage ≥II | 1.4 (1.1-2.0) | .01 |
Factors that reached statistical significance in the univariate but not the multivariable model were: insurance other than private, first-line regimens other than FCR and BR, first-line regimens other than FCR, Eastern Cooperative Oncology Group performance status 0 vs ≥1, anemia, splenomegaly as a reason for treatment initiation, and creatinine clearance at baseline.